rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

LENZ Therapeutics, Inc.

LENZ · Nasdaq

Health CareBiotechnologyNot moving yet

LENZ stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 48.6% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
18% -9 in 4 wk
Insider buys, 12 months
$1.0M
Insider sales, 12 months
$261K
Officials’ trades on record
0
Institutions holding
136 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

23 Apr – 22 Oct
18%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$25.4M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months1
Buyers · sellers4 · 1
WhoDidSharesTraded
Daniel R. ChevallardChief Financial Officerbought7,500at $8.5727 Mar 2026filed 30 Mar 2026
Evert B. SchimmelpenninkPresident, CEO and Secretarybought28,089at $8.9527 Mar 2026filed 30 Mar 2026
Jeffrey P. GeorgeDirectorbought5,592at $8.9227 Mar 2026filed 30 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders136+3 on the quarter
New · exited30 · 27
Reported value$192.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 20264,178,823$23.7M00.0%
Alpha Wave Global, LPunchanged · filed 13 Aug 20263,612,211$20.5M00.0%
FMR LLCreduced · filed 13 Aug 20263,558,905$20.2M-38,879−1.1%
Versant Venture Management, LLCunchanged · filed 12 Aug 20262,656,888$15.1M00.0%
BlackRock, Inc.added · filed 7 Aug 20262,292,121$13.0M+315,298+15.9%
Squarepoint Ops LLCadded · filed 14 Aug 20261,747,096$9.9M+240,597+16.0%
Aberdeen Group plcadded · filed 31 Jul 20261,547,883$8.8M+391,722+33.9%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20261,508,478$8.6M+639,221+73.5%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,097,755$6.2M+56,567+5.4%
72 Investment Holdings, LLCunchanged · filed 14 Aug 20261,017,751$5.8M00.0%
31 Mar 2024 – 30 Jun 2026
54102150Mar 24Sep 24Jun 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Frederic Guerard Company insiderDirector · last 15 Jun 20260 · 0
James W. McCollum Company insiderDirector · last 15 Jun 20262 · 0
Jeffrey P. George Company insiderDirector · last 15 Jun 20261 · 0
Kimberlee C. Drapkin Company insiderDirector · last 15 Jun 20260 · 0
RA CAPITAL MANAGEMENT, L.P. Company insiderDirector, 10% owner · last 15 Jun 20260 · 0
Shelley B. Thunen Company insiderDirector · last 15 Jun 20260 · 0
Zachary Scheiner Company insiderDirector · last 15 Jun 20260 · 0
Daniel R. Chevallard Company insiderChief Financial Officer · last 27 Mar 20263 · 0
Evert B. Schimmelpennink Company insiderPresident, CEO and Secretary · last 27 Mar 20261 · 0
Marc Odrich Company insiderChief Medical Officer · last 2 Jan 20260 · 0
Shawn Olsson Company insiderChief Commercial Officer · last 2 Jan 20260 · 1
Versant Vantage Ii Gp-Gp, Llc Company insider10% owner · last 30 Sep 20251 · 3

Same industry

MRNA ModernaLeading+118%
ENTX Entera BioLeading+51%
XNCR XencorLeading+44%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202597.8%
Operating profit marginFY 2025 · to 31 Dec 2025-477%
Free cash flow marginFY 2025 · to 31 Dec 2025-367%
Return on capital employedFY 2025 · to 31 Dec 2025-32.0%
Research spendFY 2025 · to 31 Dec 202597.8%
Share count trendFY 2025 · to 18 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$25.2M
Free cash flowFY 2025 · to 31 Dec 2025−$70.0M

Analyst forecasts

No analyst forecasts yet.